Cargando…
Barriers and opportunities for gemcitabine in pancreatic cancer therapy
Pancreatic ductal adenocarcinoma (PDA) has become one of the leading causes of cancer-related deaths across the world. A lack of durable responses to standard-of-care chemotherapies renders its treatment particularly challenging and largely contributes to the devastating outcome. Gemcitabine, a pyri...
Autores principales: | Beutel, Alica K., Halbrook, Christopher J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Physiological Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925166/ https://www.ncbi.nlm.nih.gov/pubmed/36571444 http://dx.doi.org/10.1152/ajpcell.00331.2022 |
Ejemplares similares
-
Gemcitabine Combination Nano Therapies for Pancreatic Cancer
por: Samanta, Kamalika, et al.
Publicado: (2019) -
Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017) -
Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002) -
Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011) -
Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance
por: Greene, Michelle K., et al.
Publicado: (2021)